Advancing cell therapy for a healthier future
Leveraging Alloy Therapeutics best-in-class iPSC platform, we are transforming CAR-T with superior potency, scalability, efficiency, and innovative model to make groundbreaking treatments accessible to all.
About Us
Pioneering the future of cell therapy with breakthrough science
We are redefining cell therapy with a best-in-class iPSC platform, enabling superior potency, scalability, and accessibility. Our groundbreaking approach accelerates CAR-T and NK therapies from discovery to clinic—making life-changing treatments available to all.
Platform
Cutting-edge innovation
We have in-licensed Alloy Therapeutics iCAR-T/NK platform, co-developed by Takeda with CiRA and Nobel Laureate Prof. Shinya Yamanaka. Our IP suite includes CRISPR, CAR, and CMC technologies, equipping us to drive next-generation cell therapies forward.
Product
Potency and scalability
Our first-in-class Allo CAR-T consistently outperforms Auto CAR-T, leveraging a Tcm phenotype for log-order expansion superiority. With a mature CMC, we are scaled up for Phase 1-2, targeting first-in-human trials in mid-2026
Strategy
Accelerating global access
7×8 Biosciences integrates cutting-edge technologies to develop transformative cell therapies. Our cash-efficient model accelerates programs from discovery through Phase 1-2 manufacturing, with continued enablement for Phase 3—bridging innovation and clinical impact to bring life-saving treatments to more patients, faster
Mission
Collaborate to Overcome Solid Tumor
Our cost efficient integration model
Efficiently develop diverse iCAR-T cells that achieve clinical proof of efficacy.
Our starting point
7×8 Bio starts with iPSC-derived T-cell CMC development—a plug-and-play cell line.
Conventional Base Camp
Most companies start their journey in cell therapy by assembling essential tools.
Science
First iPSC to surpass Auto CAR-T in potency
Alloy’s iCAR-T platform delivers stronger, more durable T-cells with a scalable, cost-efficient manufacturing process. Our breakthrough approach enhances potency, expansion, and cryopreservation, setting a new standard in CAR-T therapy.
Enhancing efficacy
By inducing a central memory phenotype, our engineered cells achieve long-term self-renewal and persistence, maintaining their functionality over time. This innovation prevents exhaustion and ensures sustained therapeutic effects, enhancing the durability and effectiveness of CAR-T treatments.
Superior expansion
Our engineered cells exhibit a significant enhancement in expansion while maintaining full functionality. Unlike conventional CAR-T cells, which often experience exhaustion, our approach supports long-lasting immune responses with sustained efficacy. This improved proliferative capacity enhances durability in vivo, offering a more robust and reliable therapeutic solution without compromising cell fitness.
Optimized potency
Our engineered T cells retain high functionality post-thaw, ensuring off-the-shelf availability and consistent therapeutic efficacy.
Partnerships
Scientific collaboration to drive innovation
Takeda’s partnership with Alloy Therapeutics validates our best-in-class iPSC platform, setting a new standard for CAR-T and NK therapies. Developed with CiRA and Nobel Laureate Prof. Shinya Yamanaka, our technology is built for superior potency, scalability, and accessibility. Join us in accelerating the next generation of cell therapies—driven by innovation and endorsed by industry leaders. Read more about the Alloy Therapeutics and Takeda collaboration.
Our Team
Meet the visionaries driving our innovative research
Leadership
Michael Kalos
Scientific Co-Founder
Veteran Cell Tx Executive
Co-inventor of Kymriah
Orange Grove Bio, Arsenal Bio,
Janssen, Eli Lilly,
Univ Penn., Carl June Labs,
City of Hope
Victor Stone
Interim CEO
Investor, Builder Platforms, Therapeutics, GP of 82VS Seed Fund, Takeda Ventures Cell and Gene Executive, Axcelead Founder
Takehiro Okumura
GM and Head of Quality
Cell Therapy Shonan, Tech Advisory Board, Parenteral Drug Assoc., Advanced Therapies, Medicinal Products
Tetsuji Hayashi
Head of CMC/MFG
Multi modality CMC, Veteran in Cell Tx, Tech Ops Lead, Process Development iCAR-T
Seiya Takahashi
Chief Operating Officer
Business Science, Hybrid Professional, Venture Partner at Hike Ventures, Arthur D Little, Astellas, CiRA
Scientific Advisors
Shin Kaneko
Scientific Collaborator
Scientific Collaborator Kyoto University, CFA Shinobi Therapeutics
Contact us
We are redefining cell therapy with a best-in-class iPSC platform, enabling superior potency, scalability, and accessibility.